nodes	percent_of_prediction	percent_of_DWPC	metapath
Methoxsalen—vitiligo—psoriasis	0.636	1	CtDrD
Methoxsalen—CYP1A1—Clobetasol propionate—psoriasis	0.0741	0.32	CbGbCtD
Methoxsalen—CYP1A2—Clobetasol propionate—psoriasis	0.0331	0.143	CbGbCtD
Methoxsalen—CYP1A1—Cholecalciferol—psoriasis	0.0258	0.111	CbGbCtD
Methoxsalen—CYP2A6—Prednisolone—psoriasis	0.0221	0.0957	CbGbCtD
Methoxsalen—CYP2A6—Dexamethasone—psoriasis	0.0131	0.0564	CbGbCtD
Methoxsalen—CYP3A4—Calcitriol—psoriasis	0.0117	0.0506	CbGbCtD
Methoxsalen—CYP1A1—Dexamethasone—psoriasis	0.0112	0.0482	CbGbCtD
Methoxsalen—CYP2A13—CYP2E1 reactions—CYP2S1—psoriasis	0.00613	0.212	CbGpPWpGaD
Methoxsalen—CYP3A4—Cholecalciferol—psoriasis	0.00603	0.0261	CbGbCtD
Methoxsalen—CYP3A4—Triamcinolone—psoriasis	0.00523	0.0226	CbGbCtD
Methoxsalen—CYP3A4—Mycophenolate mofetil—psoriasis	0.00523	0.0226	CbGbCtD
Methoxsalen—CYP3A4—Betamethasone—psoriasis	0.00449	0.0194	CbGbCtD
Methoxsalen—CYP3A4—Prednisolone—psoriasis	0.00443	0.0191	CbGbCtD
Methoxsalen—CYP3A4—Hydrocortisone—psoriasis	0.0042	0.0181	CbGbCtD
Methoxsalen—CYP3A4—Prednisone—psoriasis	0.00418	0.0181	CbGbCtD
Methoxsalen—CYP3A4—Cyclosporine—psoriasis	0.00396	0.0171	CbGbCtD
Methoxsalen—CYP2A13—Xenobiotics—CYP2S1—psoriasis	0.0038	0.132	CbGpPWpGaD
Methoxsalen—CYP3A4—Dexamethasone—psoriasis	0.00261	0.0113	CbGbCtD
Methoxsalen—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00164	0.0569	CbGpPWpGaD
Methoxsalen—CYP2A13—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00158	0.0546	CbGpPWpGaD
Methoxsalen—CYP2A13—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00156	0.0539	CbGpPWpGaD
Methoxsalen—CYP2A13—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00128	0.0443	CbGpPWpGaD
Methoxsalen—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00102	0.0353	CbGpPWpGaD
Methoxsalen—CYP1A1—Xenobiotics—CYP2S1—psoriasis	0.000759	0.0263	CbGpPWpGaD
Methoxsalen—CYP2A13—Biological oxidations—CYP2S1—psoriasis	0.000679	0.0235	CbGpPWpGaD
Methoxsalen—CYP2A13—Metapathway biotransformation—CYP2S1—psoriasis	0.00067	0.0232	CbGpPWpGaD
Methoxsalen—CYP2A13—Tryptophan metabolism—CAT—psoriasis	0.000586	0.0203	CbGpPWpGaD
Methoxsalen—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000484	0.0168	CbGpPWpGaD
Methoxsalen—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000423	0.0147	CbGpPWpGaD
Methoxsalen—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000417	0.0145	CbGpPWpGaD
Methoxsalen—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000373	0.0129	CbGpPWpGaD
Methoxsalen—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000343	0.0119	CbGpPWpGaD
Methoxsalen—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000315	0.0109	CbGpPWpGaD
Methoxsalen—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000311	0.0108	CbGpPWpGaD
Methoxsalen—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000265	0.00918	CbGpPWpGaD
Methoxsalen—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000255	0.00885	CbGpPWpGaD
Methoxsalen—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000201	0.00696	CbGpPWpGaD
Methoxsalen—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000198	0.00687	CbGpPWpGaD
Methoxsalen—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000182	0.00631	CbGpPWpGaD
Methoxsalen—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000176	0.00608	CbGpPWpGaD
Methoxsalen—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000169	0.00586	CbGpPWpGaD
Methoxsalen—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000165	0.00571	CbGpPWpGaD
Methoxsalen—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000163	0.00564	CbGpPWpGaD
Methoxsalen—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000155	0.00537	CbGpPWpGaD
Methoxsalen—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000154	0.00535	CbGpPWpGaD
Methoxsalen—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000153	0.00532	CbGpPWpGaD
Methoxsalen—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000153	0.0053	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000151	0.00524	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—NDUFA5—psoriasis	0.000137	0.00473	CbGpPWpGaD
Methoxsalen—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000136	0.0047	CbGpPWpGaD
Methoxsalen—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000134	0.00464	CbGpPWpGaD
Methoxsalen—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000134	0.00463	CbGpPWpGaD
Methoxsalen—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000132	0.00456	CbGpPWpGaD
Methoxsalen—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000126	0.00436	CbGpPWpGaD
Methoxsalen—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000124	0.0043	CbGpPWpGaD
Methoxsalen—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000117	0.00406	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—CYP2S1—psoriasis	0.000116	0.00402	CbGpPWpGaD
Methoxsalen—Skin disorder—Hydroxyurea—psoriasis	0.000104	0.001	CcSEcCtD
Methoxsalen—Dry skin—Betamethasone—psoriasis	0.000103	0.000992	CcSEcCtD
Methoxsalen—Dry skin—Dexamethasone—psoriasis	0.000103	0.000992	CcSEcCtD
Methoxsalen—Ill-defined disorder—Mycophenolic acid—psoriasis	0.000102	0.000985	CcSEcCtD
Methoxsalen—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000101	0.00351	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Acitretin—psoriasis	0.000101	0.00097	CcSEcCtD
Methoxsalen—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.0001	0.000968	CcSEcCtD
Methoxsalen—Malaise—Mycophenolic acid—psoriasis	9.94e-05	0.000957	CcSEcCtD
Methoxsalen—Vertigo—Mycophenolic acid—psoriasis	9.9e-05	0.000954	CcSEcCtD
Methoxsalen—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	9.85e-05	0.00341	CbGpPWpGaD
Methoxsalen—Rash—Calcitriol—psoriasis	9.69e-05	0.000934	CcSEcCtD
Methoxsalen—Dermatitis—Calcitriol—psoriasis	9.68e-05	0.000933	CcSEcCtD
Methoxsalen—Pruritus—Acitretin—psoriasis	9.68e-05	0.000932	CcSEcCtD
Methoxsalen—Pruritus—Fluocinolone Acetonide—psoriasis	9.65e-05	0.000929	CcSEcCtD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	9.64e-05	0.00334	CbGpPWpGaD
Methoxsalen—Headache—Calcitriol—psoriasis	9.63e-05	0.000928	CcSEcCtD
Methoxsalen—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	9.47e-05	0.00328	CbGpPWpGaD
Methoxsalen—Dyspepsia—Hydroxyurea—psoriasis	9.45e-05	0.00091	CcSEcCtD
Methoxsalen—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	9.27e-05	0.00321	CbGpPWpGaD
Methoxsalen—Gastrointestinal disorder—Hydroxyurea—psoriasis	9.27e-05	0.000893	CcSEcCtD
Methoxsalen—Discomfort—Mycophenolic acid—psoriasis	9.27e-05	0.000893	CcSEcCtD
Methoxsalen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.23e-05	0.0032	CbGpPWpGaD
Methoxsalen—Arrhythmia—Cyclosporine—psoriasis	9.15e-05	0.000881	CcSEcCtD
Methoxsalen—Nausea—Calcitriol—psoriasis	9.13e-05	0.00088	CcSEcCtD
Methoxsalen—Dizziness—Acitretin—psoriasis	9.04e-05	0.000871	CcSEcCtD
Methoxsalen—Dizziness—Fluocinolone Acetonide—psoriasis	9.02e-05	0.000869	CcSEcCtD
Methoxsalen—Oedema—Mycophenolic acid—psoriasis	8.99e-05	0.000866	CcSEcCtD
Methoxsalen—Dry skin—Prednisone—psoriasis	8.97e-05	0.000864	CcSEcCtD
Methoxsalen—Infection—Mycophenolic acid—psoriasis	8.93e-05	0.000861	CcSEcCtD
Methoxsalen—Arrhythmia—Mycophenolate mofetil—psoriasis	8.92e-05	0.00086	CcSEcCtD
Methoxsalen—Feeling abnormal—Hydroxyurea—psoriasis	8.85e-05	0.000852	CcSEcCtD
Methoxsalen—Tension—Cyclosporine—psoriasis	8.75e-05	0.000843	CcSEcCtD
Methoxsalen—Skin disorder—Mycophenolic acid—psoriasis	8.74e-05	0.000841	CcSEcCtD
Methoxsalen—Dysgeusia—Cyclosporine—psoriasis	8.73e-05	0.000841	CcSEcCtD
Methoxsalen—Nervousness—Cyclosporine—psoriasis	8.66e-05	0.000834	CcSEcCtD
Methoxsalen—CYP1A2—Biological oxidations—CYP2S1—psoriasis	8.65e-05	0.003	CbGpPWpGaD
Methoxsalen—Rash—Acitretin—psoriasis	8.62e-05	0.000831	CcSEcCtD
Methoxsalen—Dermatitis—Acitretin—psoriasis	8.62e-05	0.00083	CcSEcCtD
Methoxsalen—Rash—Fluocinolone Acetonide—psoriasis	8.6e-05	0.000828	CcSEcCtD
Methoxsalen—Dermatitis—Fluocinolone Acetonide—psoriasis	8.59e-05	0.000827	CcSEcCtD
Methoxsalen—Muscle spasms—Cyclosporine—psoriasis	8.57e-05	0.000825	CcSEcCtD
Methoxsalen—Headache—Acitretin—psoriasis	8.57e-05	0.000825	CcSEcCtD
Methoxsalen—Headache—Fluocinolone Acetonide—psoriasis	8.54e-05	0.000823	CcSEcCtD
Methoxsalen—Tension—Mycophenolate mofetil—psoriasis	8.53e-05	0.000822	CcSEcCtD
Methoxsalen—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	8.53e-05	0.00296	CbGpPWpGaD
Methoxsalen—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	8.52e-05	0.00295	CbGpPWpGaD
Methoxsalen—Dysgeusia—Mycophenolate mofetil—psoriasis	8.52e-05	0.00082	CcSEcCtD
Methoxsalen—Body temperature increased—Hydroxyurea—psoriasis	8.49e-05	0.000818	CcSEcCtD
Methoxsalen—Nervousness—Mycophenolate mofetil—psoriasis	8.45e-05	0.000813	CcSEcCtD
Methoxsalen—Hypotension—Mycophenolic acid—psoriasis	8.4e-05	0.000809	CcSEcCtD
Methoxsalen—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	8.39e-05	0.00291	CbGpPWpGaD
Methoxsalen—Muscle spasms—Mycophenolate mofetil—psoriasis	8.36e-05	0.000805	CcSEcCtD
Methoxsalen—Arrhythmia—Prednisolone—psoriasis	8.32e-05	0.000802	CcSEcCtD
Methoxsalen—Ill-defined disorder—Cyclosporine—psoriasis	8.27e-05	0.000797	CcSEcCtD
Methoxsalen—Insomnia—Mycophenolic acid—psoriasis	8.13e-05	0.000783	CcSEcCtD
Methoxsalen—Arrhythmia—Hydrocortisone—psoriasis	8.13e-05	0.000783	CcSEcCtD
Methoxsalen—Nausea—Acitretin—psoriasis	8.12e-05	0.000782	CcSEcCtD
Methoxsalen—Erythema—Prednisolone—psoriasis	8.11e-05	0.000781	CcSEcCtD
Methoxsalen—Nausea—Fluocinolone Acetonide—psoriasis	8.1e-05	0.00078	CcSEcCtD
Methoxsalen—Ill-defined disorder—Mycophenolate mofetil—psoriasis	8.07e-05	0.000777	CcSEcCtD
Methoxsalen—Malaise—Cyclosporine—psoriasis	8.04e-05	0.000774	CcSEcCtD
Methoxsalen—Vertigo—Cyclosporine—psoriasis	8.01e-05	0.000771	CcSEcCtD
Methoxsalen—Erythema—Hydrocortisone—psoriasis	7.92e-05	0.000763	CcSEcCtD
Methoxsalen—Dyspepsia—Mycophenolic acid—psoriasis	7.92e-05	0.000762	CcSEcCtD
Methoxsalen—Hypersensitivity—Hydroxyurea—psoriasis	7.91e-05	0.000762	CcSEcCtD
Methoxsalen—Malaise—Mycophenolate mofetil—psoriasis	7.84e-05	0.000755	CcSEcCtD
Methoxsalen—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	7.82e-05	0.00271	CbGpPWpGaD
Methoxsalen—Vertigo—Mycophenolate mofetil—psoriasis	7.81e-05	0.000753	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Mycophenolic acid—psoriasis	7.76e-05	0.000748	CcSEcCtD
Methoxsalen—Arrhythmia—Triamcinolone—psoriasis	7.66e-05	0.000737	CcSEcCtD
Methoxsalen—CYP1A1—Oxidative Stress—NFKB1—psoriasis	7.61e-05	0.00264	CbGpPWpGaD
Methoxsalen—Ill-defined disorder—Prednisolone—psoriasis	7.53e-05	0.000725	CcSEcCtD
Methoxsalen—Depression—Prednisone—psoriasis	7.52e-05	0.000724	CcSEcCtD
Methoxsalen—Discomfort—Cyclosporine—psoriasis	7.5e-05	0.000722	CcSEcCtD
Methoxsalen—CYP1A2—Tryptophan metabolism—CAT—psoriasis	7.46e-05	0.00259	CbGpPWpGaD
Methoxsalen—Erythema—Triamcinolone—psoriasis	7.46e-05	0.000718	CcSEcCtD
Methoxsalen—Feeling abnormal—Mycophenolic acid—psoriasis	7.41e-05	0.000714	CcSEcCtD
Methoxsalen—Ill-defined disorder—Hydrocortisone—psoriasis	7.35e-05	0.000708	CcSEcCtD
Methoxsalen—Malaise—Prednisolone—psoriasis	7.32e-05	0.000705	CcSEcCtD
Methoxsalen—Discomfort—Mycophenolate mofetil—psoriasis	7.31e-05	0.000705	CcSEcCtD
Methoxsalen—Dysgeusia—Triamcinolone—psoriasis	7.31e-05	0.000704	CcSEcCtD
Methoxsalen—Vertigo—Prednisolone—psoriasis	7.29e-05	0.000702	CcSEcCtD
Methoxsalen—Oedema—Cyclosporine—psoriasis	7.28e-05	0.000701	CcSEcCtD
Methoxsalen—Infection—Cyclosporine—psoriasis	7.23e-05	0.000696	CcSEcCtD
Methoxsalen—Malaise—Hydrocortisone—psoriasis	7.14e-05	0.000688	CcSEcCtD
Methoxsalen—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.12e-05	0.00247	CbGpPWpGaD
Methoxsalen—Vertigo—Hydrocortisone—psoriasis	7.12e-05	0.000686	CcSEcCtD
Methoxsalen—Body temperature increased—Mycophenolic acid—psoriasis	7.11e-05	0.000685	CcSEcCtD
Methoxsalen—Dizziness—Hydroxyurea—psoriasis	7.1e-05	0.000684	CcSEcCtD
Methoxsalen—Oedema—Mycophenolate mofetil—psoriasis	7.1e-05	0.000684	CcSEcCtD
Methoxsalen—Skin disorder—Cyclosporine—psoriasis	7.07e-05	0.000681	CcSEcCtD
Methoxsalen—Infection—Mycophenolate mofetil—psoriasis	7.05e-05	0.000679	CcSEcCtD
Methoxsalen—Arrhythmia—Dexamethasone—psoriasis	6.95e-05	0.000669	CcSEcCtD
Methoxsalen—Arrhythmia—Betamethasone—psoriasis	6.95e-05	0.000669	CcSEcCtD
Methoxsalen—Ill-defined disorder—Triamcinolone—psoriasis	6.92e-05	0.000667	CcSEcCtD
Methoxsalen—Skin disorder—Mycophenolate mofetil—psoriasis	6.89e-05	0.000664	CcSEcCtD
Methoxsalen—Discomfort—Prednisolone—psoriasis	6.82e-05	0.000657	CcSEcCtD
Methoxsalen—Rash—Hydroxyurea—psoriasis	6.77e-05	0.000652	CcSEcCtD
Methoxsalen—Erythema—Dexamethasone—psoriasis	6.77e-05	0.000652	CcSEcCtD
Methoxsalen—Erythema—Betamethasone—psoriasis	6.77e-05	0.000652	CcSEcCtD
Methoxsalen—Dermatitis—Hydroxyurea—psoriasis	6.76e-05	0.000651	CcSEcCtD
Methoxsalen—Malaise—Triamcinolone—psoriasis	6.73e-05	0.000648	CcSEcCtD
Methoxsalen—Headache—Hydroxyurea—psoriasis	6.73e-05	0.000648	CcSEcCtD
Methoxsalen—Vertigo—Triamcinolone—psoriasis	6.7e-05	0.000646	CcSEcCtD
Methoxsalen—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.68e-05	0.00231	CbGpPWpGaD
Methoxsalen—Discomfort—Hydrocortisone—psoriasis	6.66e-05	0.000642	CcSEcCtD
Methoxsalen—Hypotension—Mycophenolate mofetil—psoriasis	6.63e-05	0.000639	CcSEcCtD
Methoxsalen—Oedema—Prednisolone—psoriasis	6.62e-05	0.000638	CcSEcCtD
Methoxsalen—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.59e-05	0.00228	CbGpPWpGaD
Methoxsalen—Insomnia—Cyclosporine—psoriasis	6.58e-05	0.000634	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.5e-05	0.00225	CbGpPWpGaD
Methoxsalen—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	6.49e-05	0.00225	CbGpPWpGaD
Methoxsalen—Oedema—Hydrocortisone—psoriasis	6.47e-05	0.000623	CcSEcCtD
Methoxsalen—Photosensitivity reaction—Methotrexate—psoriasis	6.45e-05	0.000622	CcSEcCtD
Methoxsalen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.43e-05	0.00223	CbGpPWpGaD
Methoxsalen—Infection—Hydrocortisone—psoriasis	6.42e-05	0.000619	CcSEcCtD
Methoxsalen—Insomnia—Mycophenolate mofetil—psoriasis	6.42e-05	0.000618	CcSEcCtD
Methoxsalen—Dyspepsia—Cyclosporine—psoriasis	6.4e-05	0.000617	CcSEcCtD
Methoxsalen—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	6.39e-05	0.00221	CbGpPWpGaD
Methoxsalen—Nausea—Hydroxyurea—psoriasis	6.38e-05	0.000614	CcSEcCtD
Methoxsalen—Pruritus—Mycophenolic acid—psoriasis	6.36e-05	0.000613	CcSEcCtD
Methoxsalen—Depression—Methotrexate—psoriasis	6.29e-05	0.000605	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Cyclosporine—psoriasis	6.28e-05	0.000605	CcSEcCtD
Methoxsalen—Skin disorder—Hydrocortisone—psoriasis	6.28e-05	0.000605	CcSEcCtD
Methoxsalen—Ill-defined disorder—Dexamethasone—psoriasis	6.28e-05	0.000605	CcSEcCtD
Methoxsalen—Ill-defined disorder—Betamethasone—psoriasis	6.28e-05	0.000605	CcSEcCtD
Methoxsalen—Discomfort—Triamcinolone—psoriasis	6.28e-05	0.000604	CcSEcCtD
Methoxsalen—Dyspepsia—Mycophenolate mofetil—psoriasis	6.25e-05	0.000602	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	6.13e-05	0.00059	CcSEcCtD
Methoxsalen—Malaise—Dexamethasone—psoriasis	6.1e-05	0.000588	CcSEcCtD
Methoxsalen—Malaise—Betamethasone—psoriasis	6.1e-05	0.000588	CcSEcCtD
Methoxsalen—Oedema—Triamcinolone—psoriasis	6.09e-05	0.000586	CcSEcCtD
Methoxsalen—Vertigo—Dexamethasone—psoriasis	6.08e-05	0.000586	CcSEcCtD
Methoxsalen—Vertigo—Betamethasone—psoriasis	6.08e-05	0.000586	CcSEcCtD
Methoxsalen—Arrhythmia—Prednisone—psoriasis	6.05e-05	0.000583	CcSEcCtD
Methoxsalen—Infection—Triamcinolone—psoriasis	6.05e-05	0.000583	CcSEcCtD
Methoxsalen—Hypotension—Hydrocortisone—psoriasis	6.04e-05	0.000582	CcSEcCtD
Methoxsalen—Feeling abnormal—Cyclosporine—psoriasis	6e-05	0.000577	CcSEcCtD
Methoxsalen—Insomnia—Prednisolone—psoriasis	5.99e-05	0.000577	CcSEcCtD
Methoxsalen—Dizziness—Mycophenolic acid—psoriasis	5.95e-05	0.000573	CcSEcCtD
Methoxsalen—Erythema—Prednisone—psoriasis	5.89e-05	0.000568	CcSEcCtD
Methoxsalen—Feeling abnormal—Mycophenolate mofetil—psoriasis	5.85e-05	0.000563	CcSEcCtD
Methoxsalen—Insomnia—Hydrocortisone—psoriasis	5.85e-05	0.000563	CcSEcCtD
Methoxsalen—Urticaria—Cyclosporine—psoriasis	5.78e-05	0.000557	CcSEcCtD
Methoxsalen—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.76e-05	0.002	CbGpPWpGaD
Methoxsalen—Body temperature increased—Cyclosporine—psoriasis	5.75e-05	0.000554	CcSEcCtD
Methoxsalen—Discomfort—Betamethasone—psoriasis	5.69e-05	0.000548	CcSEcCtD
Methoxsalen—Discomfort—Dexamethasone—psoriasis	5.69e-05	0.000548	CcSEcCtD
Methoxsalen—Dyspepsia—Hydrocortisone—psoriasis	5.69e-05	0.000548	CcSEcCtD
Methoxsalen—Rash—Mycophenolic acid—psoriasis	5.67e-05	0.000546	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—CARM1—psoriasis	5.67e-05	0.00197	CbGpPWpGaD
Methoxsalen—Dermatitis—Mycophenolic acid—psoriasis	5.67e-05	0.000546	CcSEcCtD
Methoxsalen—Urticaria—Mycophenolate mofetil—psoriasis	5.64e-05	0.000543	CcSEcCtD
Methoxsalen—Headache—Mycophenolic acid—psoriasis	5.63e-05	0.000543	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.62e-05	0.00195	CbGpPWpGaD
Methoxsalen—Body temperature increased—Mycophenolate mofetil—psoriasis	5.61e-05	0.00054	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.58e-05	0.000538	CcSEcCtD
Methoxsalen—Oedema—Dexamethasone—psoriasis	5.52e-05	0.000532	CcSEcCtD
Methoxsalen—Oedema—Betamethasone—psoriasis	5.52e-05	0.000532	CcSEcCtD
Methoxsalen—Insomnia—Triamcinolone—psoriasis	5.51e-05	0.00053	CcSEcCtD
Methoxsalen—Infection—Dexamethasone—psoriasis	5.49e-05	0.000529	CcSEcCtD
Methoxsalen—Infection—Betamethasone—psoriasis	5.49e-05	0.000529	CcSEcCtD
Methoxsalen—Ill-defined disorder—Prednisone—psoriasis	5.47e-05	0.000527	CcSEcCtD
Methoxsalen—Feeling abnormal—Prednisolone—psoriasis	5.46e-05	0.000525	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.41e-05	0.00187	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Cyclosporine—psoriasis	5.36e-05	0.000516	CcSEcCtD
Methoxsalen—Dyspepsia—Triamcinolone—psoriasis	5.36e-05	0.000516	CcSEcCtD
Methoxsalen—Nausea—Mycophenolic acid—psoriasis	5.34e-05	0.000514	CcSEcCtD
Methoxsalen—Feeling abnormal—Hydrocortisone—psoriasis	5.33e-05	0.000513	CcSEcCtD
Methoxsalen—Malaise—Prednisone—psoriasis	5.32e-05	0.000512	CcSEcCtD
Methoxsalen—Vertigo—Prednisone—psoriasis	5.3e-05	0.00051	CcSEcCtD
Methoxsalen—Urticaria—Prednisolone—psoriasis	5.26e-05	0.000507	CcSEcCtD
Methoxsalen—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.23e-05	0.000504	CcSEcCtD
Methoxsalen—Hypotension—Dexamethasone—psoriasis	5.16e-05	0.000497	CcSEcCtD
Methoxsalen—Hypotension—Betamethasone—psoriasis	5.16e-05	0.000497	CcSEcCtD
Methoxsalen—Pruritus—Cyclosporine—psoriasis	5.15e-05	0.000496	CcSEcCtD
Methoxsalen—Urticaria—Hydrocortisone—psoriasis	5.14e-05	0.000495	CcSEcCtD
Methoxsalen—Body temperature increased—Hydrocortisone—psoriasis	5.11e-05	0.000492	CcSEcCtD
Methoxsalen—Pruritus—Mycophenolate mofetil—psoriasis	5.02e-05	0.000484	CcSEcCtD
Methoxsalen—Feeling abnormal—Triamcinolone—psoriasis	5.02e-05	0.000483	CcSEcCtD
Methoxsalen—Insomnia—Dexamethasone—psoriasis	5e-05	0.000481	CcSEcCtD
Methoxsalen—Insomnia—Betamethasone—psoriasis	5e-05	0.000481	CcSEcCtD
Methoxsalen—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	4.99e-05	0.00173	CbGpPWpGaD
Methoxsalen—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.97e-05	0.00172	CbGpPWpGaD
Methoxsalen—Discomfort—Prednisone—psoriasis	4.96e-05	0.000478	CcSEcCtD
Methoxsalen—Erythema—Methotrexate—psoriasis	4.93e-05	0.000474	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.91e-05	0.0017	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Prednisolone—psoriasis	4.88e-05	0.00047	CcSEcCtD
Methoxsalen—Dyspepsia—Betamethasone—psoriasis	4.86e-05	0.000468	CcSEcCtD
Methoxsalen—Dyspepsia—Dexamethasone—psoriasis	4.86e-05	0.000468	CcSEcCtD
Methoxsalen—Urticaria—Triamcinolone—psoriasis	4.84e-05	0.000466	CcSEcCtD
Methoxsalen—Dysgeusia—Methotrexate—psoriasis	4.82e-05	0.000465	CcSEcCtD
Methoxsalen—Body temperature increased—Triamcinolone—psoriasis	4.81e-05	0.000464	CcSEcCtD
Methoxsalen—Dizziness—Cyclosporine—psoriasis	4.81e-05	0.000463	CcSEcCtD
Methoxsalen—Oedema—Prednisone—psoriasis	4.81e-05	0.000463	CcSEcCtD
Methoxsalen—Infection—Prednisone—psoriasis	4.78e-05	0.00046	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Dexamethasone—psoriasis	4.77e-05	0.000459	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Betamethasone—psoriasis	4.77e-05	0.000459	CcSEcCtD
Methoxsalen—Hypersensitivity—Hydrocortisone—psoriasis	4.76e-05	0.000459	CcSEcCtD
Methoxsalen—Dizziness—Mycophenolate mofetil—psoriasis	4.69e-05	0.000452	CcSEcCtD
Methoxsalen—Skin disorder—Prednisone—psoriasis	4.67e-05	0.00045	CcSEcCtD
Methoxsalen—Rash—Cyclosporine—psoriasis	4.59e-05	0.000442	CcSEcCtD
Methoxsalen—Dermatitis—Cyclosporine—psoriasis	4.58e-05	0.000441	CcSEcCtD
Methoxsalen—Pruritus—Hydrocortisone—psoriasis	4.57e-05	0.000441	CcSEcCtD
Methoxsalen—Ill-defined disorder—Methotrexate—psoriasis	4.57e-05	0.00044	CcSEcCtD
Methoxsalen—Headache—Cyclosporine—psoriasis	4.56e-05	0.000439	CcSEcCtD
Methoxsalen—Feeling abnormal—Dexamethasone—psoriasis	4.55e-05	0.000438	CcSEcCtD
Methoxsalen—Feeling abnormal—Betamethasone—psoriasis	4.55e-05	0.000438	CcSEcCtD
Methoxsalen—Hypersensitivity—Triamcinolone—psoriasis	4.49e-05	0.000432	CcSEcCtD
Methoxsalen—Rash—Mycophenolate mofetil—psoriasis	4.48e-05	0.000431	CcSEcCtD
Methoxsalen—Dermatitis—Mycophenolate mofetil—psoriasis	4.47e-05	0.000431	CcSEcCtD
Methoxsalen—Headache—Mycophenolate mofetil—psoriasis	4.45e-05	0.000428	CcSEcCtD
Methoxsalen—Malaise—Methotrexate—psoriasis	4.44e-05	0.000428	CcSEcCtD
Methoxsalen—Vertigo—Methotrexate—psoriasis	4.43e-05	0.000426	CcSEcCtD
Methoxsalen—Urticaria—Dexamethasone—psoriasis	4.39e-05	0.000423	CcSEcCtD
Methoxsalen—Urticaria—Betamethasone—psoriasis	4.39e-05	0.000423	CcSEcCtD
Methoxsalen—Dizziness—Prednisolone—psoriasis	4.38e-05	0.000422	CcSEcCtD
Methoxsalen—Body temperature increased—Betamethasone—psoriasis	4.37e-05	0.000421	CcSEcCtD
Methoxsalen—Body temperature increased—Dexamethasone—psoriasis	4.37e-05	0.000421	CcSEcCtD
Methoxsalen—Insomnia—Prednisone—psoriasis	4.35e-05	0.000419	CcSEcCtD
Methoxsalen—Nausea—Cyclosporine—psoriasis	4.32e-05	0.000416	CcSEcCtD
Methoxsalen—Pruritus—Triamcinolone—psoriasis	4.31e-05	0.000415	CcSEcCtD
Methoxsalen—Dizziness—Hydrocortisone—psoriasis	4.28e-05	0.000412	CcSEcCtD
Methoxsalen—Dyspepsia—Prednisone—psoriasis	4.23e-05	0.000408	CcSEcCtD
Methoxsalen—Nausea—Mycophenolate mofetil—psoriasis	4.22e-05	0.000406	CcSEcCtD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.21e-05	0.00146	CbGpPWpGaD
Methoxsalen—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.21e-05	0.00146	CbGpPWpGaD
Methoxsalen—Rash—Prednisolone—psoriasis	4.17e-05	0.000402	CcSEcCtD
Methoxsalen—Dermatitis—Prednisolone—psoriasis	4.17e-05	0.000402	CcSEcCtD
Methoxsalen—Headache—Prednisolone—psoriasis	4.15e-05	0.000399	CcSEcCtD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.14e-05	0.00144	CbGpPWpGaD
Methoxsalen—Discomfort—Methotrexate—psoriasis	4.14e-05	0.000399	CcSEcCtD
Methoxsalen—Rash—Hydrocortisone—psoriasis	4.08e-05	0.000393	CcSEcCtD
Methoxsalen—Dermatitis—Hydrocortisone—psoriasis	4.07e-05	0.000392	CcSEcCtD
Methoxsalen—Headache—Hydrocortisone—psoriasis	4.05e-05	0.00039	CcSEcCtD
Methoxsalen—Dizziness—Triamcinolone—psoriasis	4.03e-05	0.000388	CcSEcCtD
Methoxsalen—Infection—Methotrexate—psoriasis	3.99e-05	0.000385	CcSEcCtD
Methoxsalen—Feeling abnormal—Prednisone—psoriasis	3.96e-05	0.000382	CcSEcCtD
Methoxsalen—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	3.94e-05	0.00137	CbGpPWpGaD
Methoxsalen—Nausea—Prednisolone—psoriasis	3.93e-05	0.000379	CcSEcCtD
Methoxsalen—Pruritus—Dexamethasone—psoriasis	3.91e-05	0.000376	CcSEcCtD
Methoxsalen—Pruritus—Betamethasone—psoriasis	3.91e-05	0.000376	CcSEcCtD
Methoxsalen—Skin disorder—Methotrexate—psoriasis	3.91e-05	0.000376	CcSEcCtD
Methoxsalen—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	3.86e-05	0.00134	CbGpPWpGaD
Methoxsalen—Nausea—Hydrocortisone—psoriasis	3.84e-05	0.00037	CcSEcCtD
Methoxsalen—Rash—Triamcinolone—psoriasis	3.84e-05	0.00037	CcSEcCtD
Methoxsalen—Dermatitis—Triamcinolone—psoriasis	3.84e-05	0.000369	CcSEcCtD
Methoxsalen—Urticaria—Prednisone—psoriasis	3.82e-05	0.000368	CcSEcCtD
Methoxsalen—Headache—Triamcinolone—psoriasis	3.81e-05	0.000367	CcSEcCtD
Methoxsalen—Body temperature increased—Prednisone—psoriasis	3.8e-05	0.000366	CcSEcCtD
Methoxsalen—Hypotension—Methotrexate—psoriasis	3.76e-05	0.000362	CcSEcCtD
Methoxsalen—CYP2A6—Metabolism—NDUFA5—psoriasis	3.66e-05	0.00127	CbGpPWpGaD
Methoxsalen—Dizziness—Dexamethasone—psoriasis	3.65e-05	0.000352	CcSEcCtD
Methoxsalen—Dizziness—Betamethasone—psoriasis	3.65e-05	0.000352	CcSEcCtD
Methoxsalen—Insomnia—Methotrexate—psoriasis	3.64e-05	0.00035	CcSEcCtD
Methoxsalen—Nausea—Triamcinolone—psoriasis	3.62e-05	0.000348	CcSEcCtD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.58e-05	0.00124	CbGpPWpGaD
Methoxsalen—Hypersensitivity—Prednisone—psoriasis	3.54e-05	0.000341	CcSEcCtD
Methoxsalen—Dyspepsia—Methotrexate—psoriasis	3.54e-05	0.000341	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—CAT—psoriasis	3.49e-05	0.00121	CbGpPWpGaD
Methoxsalen—Rash—Betamethasone—psoriasis	3.48e-05	0.000335	CcSEcCtD
Methoxsalen—Rash—Dexamethasone—psoriasis	3.48e-05	0.000335	CcSEcCtD
Methoxsalen—Dermatitis—Betamethasone—psoriasis	3.48e-05	0.000335	CcSEcCtD
Methoxsalen—Dermatitis—Dexamethasone—psoriasis	3.48e-05	0.000335	CcSEcCtD
Methoxsalen—Gastrointestinal disorder—Methotrexate—psoriasis	3.47e-05	0.000334	CcSEcCtD
Methoxsalen—Headache—Dexamethasone—psoriasis	3.46e-05	0.000333	CcSEcCtD
Methoxsalen—Headache—Betamethasone—psoriasis	3.46e-05	0.000333	CcSEcCtD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.45e-05	0.0012	CbGpPWpGaD
Methoxsalen—Pruritus—Prednisone—psoriasis	3.4e-05	0.000328	CcSEcCtD
Methoxsalen—Feeling abnormal—Methotrexate—psoriasis	3.31e-05	0.000319	CcSEcCtD
Methoxsalen—Nausea—Betamethasone—psoriasis	3.28e-05	0.000316	CcSEcCtD
Methoxsalen—Nausea—Dexamethasone—psoriasis	3.28e-05	0.000316	CcSEcCtD
Methoxsalen—Urticaria—Methotrexate—psoriasis	3.19e-05	0.000308	CcSEcCtD
Methoxsalen—Dizziness—Prednisone—psoriasis	3.18e-05	0.000306	CcSEcCtD
Methoxsalen—Body temperature increased—Methotrexate—psoriasis	3.18e-05	0.000306	CcSEcCtD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.13e-05	0.00108	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—CYP2S1—psoriasis	3.11e-05	0.00108	CbGpPWpGaD
Methoxsalen—Rash—Prednisone—psoriasis	3.03e-05	0.000292	CcSEcCtD
Methoxsalen—Dermatitis—Prednisone—psoriasis	3.03e-05	0.000292	CcSEcCtD
Methoxsalen—Headache—Prednisone—psoriasis	3.01e-05	0.00029	CcSEcCtD
Methoxsalen—Hypersensitivity—Methotrexate—psoriasis	2.96e-05	0.000285	CcSEcCtD
Methoxsalen—Nausea—Prednisone—psoriasis	2.86e-05	0.000275	CcSEcCtD
Methoxsalen—Pruritus—Methotrexate—psoriasis	2.84e-05	0.000274	CcSEcCtD
Methoxsalen—CYP1A1—Metabolism—NDUFA5—psoriasis	2.73e-05	0.000946	CbGpPWpGaD
Methoxsalen—CYP2A13—Metabolism—APOE—psoriasis	2.71e-05	0.000939	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.68e-05	0.00093	CbGpPWpGaD
Methoxsalen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.68e-05	0.00093	CbGpPWpGaD
Methoxsalen—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	2.66e-05	0.000922	CbGpPWpGaD
Methoxsalen—Dizziness—Methotrexate—psoriasis	2.66e-05	0.000256	CcSEcCtD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.54e-05	0.000882	CbGpPWpGaD
Methoxsalen—Rash—Methotrexate—psoriasis	2.54e-05	0.000244	CcSEcCtD
Methoxsalen—Dermatitis—Methotrexate—psoriasis	2.53e-05	0.000244	CcSEcCtD
Methoxsalen—Headache—Methotrexate—psoriasis	2.52e-05	0.000243	CcSEcCtD
Methoxsalen—Nausea—Methotrexate—psoriasis	2.39e-05	0.00023	CcSEcCtD
Methoxsalen—CYP2A13—Metabolism—PPARG—psoriasis	2.36e-05	0.000818	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—CYP2S1—psoriasis	2.32e-05	0.000804	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—NDUFA5—psoriasis	1.74e-05	0.000603	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.62e-05	0.000562	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—CARM1—psoriasis	1.52e-05	0.000527	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—CYP2S1—psoriasis	1.48e-05	0.000513	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—NDUFA5—psoriasis	1.34e-05	0.000465	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.22e-05	0.000421	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—CYP2S1—psoriasis	1.14e-05	0.000396	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—CARM1—psoriasis	1.13e-05	0.000393	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.06e-05	0.000367	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—CAT—psoriasis	9.35e-06	0.000324	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.75e-06	0.000269	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—APOE—psoriasis	7.27e-06	0.000252	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—CARM1—psoriasis	7.23e-06	0.00025	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—CAT—psoriasis	6.97e-06	0.000242	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.75e-06	0.000234	CbGpPWpGaD
Methoxsalen—CYP2A6—Metabolism—PPARG—psoriasis	6.33e-06	0.000219	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—CARM1—psoriasis	5.58e-06	0.000193	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—APOE—psoriasis	5.42e-06	0.000188	CbGpPWpGaD
Methoxsalen—CYP1A1—Metabolism—PPARG—psoriasis	4.72e-06	0.000163	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—CAT—psoriasis	4.44e-06	0.000154	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—APOE—psoriasis	3.45e-06	0.00012	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—CAT—psoriasis	3.43e-06	0.000119	CbGpPWpGaD
Methoxsalen—CYP1A2—Metabolism—PPARG—psoriasis	3.01e-06	0.000104	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—APOE—psoriasis	2.66e-06	9.24e-05	CbGpPWpGaD
Methoxsalen—CYP3A4—Metabolism—PPARG—psoriasis	2.32e-06	8.05e-05	CbGpPWpGaD
